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FOLLOWING
WING TUMOR TYPES
WE CURRENTLY HAVE TRIALS RECRUITING THE FOLLO
(alphabetical list):
histiocytosis), lymphoma, mast cell tumors,
DOGS- anal sac adenocarcinomas, histiocytic sarcoma (malignant histiocytosis
melanoma, multiple myeloma, osteosarcoma
osteosarcoma, squamous cell carcinoma (oral), thyroid carcinoma,
carcinoma transitional cell
carcinoma (bladder)
CATS- lymphoma, squamous
quamous cell carcinoma (oral)
GRADE
NEW TUMOR TYPES! Tumor type: CANINE B AND T CELL LYMPHOMA (HIGH GRADE),
OSTEOSARCOMA, and MULTIPLE MYELOMA
Trial: Evaluation of oncolytic viruses in canine cancer.
The goal of this trial is to evaluate the response of various tumor types to an oncolytic virus designed to infect
cancer cells but not normal cells. This project is a collaboration with the Mayo clinic and funded by the Morris
Animal Foundation (B cell lymphoma) and the UT Center of Excellence (T cell lymphoma, Osteosarcoma, Multiple
Myeloma) evaluating a new and exciting approach to can
cancer treatment! This trial is fully funded.
funded (PI- Dr. Sara
Allstadt Frazier; contact Oncology at (865) 974
974-8387 or Gina Galyon at 865-755-8151
8151 or Dr. Frazier at
sarafrazier@utk.edu).. Patients ideally should be off other therapies (including steroids) for 2 weeks prior to
enrollment. Trial period is for 30 days (~4 visits to UT).
Tumor type: FELINE ORAL SQUAMOUS CELL CARCINOMAS.
Trial: Phase I trial of nanoencapsulated antisense CK
CK2.
This trial aims to evaluate the tolerability of a novel gene therapy against CK2 in a targeted nanocapsule that homes
specifically to cancer cells. Cats with oral squamous cell carcinoma confined to the oral cavity ++ regional lymph
nodes may be eligible.
ible. The trial period is 3 weeks, with two treatments per week. Pre
Pre- and post-treatment
post
biopsies
are required to assess CK2 expression. The trial includes financial incentives, with drug supplied at no cost
and cost of pre- and post-treatment
treatment biopsies and labwork is covered during treatment.
treatment PI – Dr. Claire
Cannon, clairecannon@utk.edu or 865-974
974-8387.
SARCOMA.
Tumor type: CANINE HISTIOCYTIC S
Trial: Phase II, Open Label Trial of Paccal Vet® (water
(water-soluble micellar
ellar paclitaxel) in Dogs with
Histiocytic Sarcoma.
The trial will evaluate a new canine chemotherapy agent, Paccal Vet, for canine histiocytic sarcoma. Paccal Vet has
been studied in other canine tumors. This trial includes financial incentives to the client (Paccal vet provided at
no cost, additional staging tests are covered to determine response). Trial period is a minimum of 6 weeks (3
required visits to UT), but additional Paccal Vet provided if dog responds to treatment. PI
PI- Dr. Sara Allstadt Frazier,
contact at sarafrazier@utk.edu or Gina Galyon at 865
865-755-8151. Patients need to be off other therapies (including
steroids) for 2 weeks prior to enrollment.
Tumor type: CANINE LYMPHOMA.
Trial: Preclinical Comparison of Three Indenoisoquinolines Candidates in Tumor-Bearing
Tumor
Dogs.
The goal of this trial is to evaluate 3 new drugs in tumor
tumor-bearing
bearing dogs and define the pharmacokinetics,
pharmacodynamics, and toxicity profile of each agent. Dogs must have confirmed lymphoma to be eligible for the
trial. For more information contact investigators: Claire Cannon or research technician
echnician Gina Galyon at 865-755865
8151. This trial is fully funded and clients will receive a $1000 incentive at the end of the study period (29 days)
to use for future therapy.
NEW! Tumor type: FELINE HIGH GRADE LY
LYMPHOMA.
Trial: Efficacy of High-dose L-asparaginase
sparaginase and Impact on Ammonia and Amino Acid Levels in Cats
with High Grade Lymphoma.
The trial will evaluate the response of cats with lymphoma to a single treatment with L
L-asparaginase.
asparaginase. The trial
period is one week and includes three visits to UT for blood sampling and re-staging
staging tests. This trial is funded and
includes a free dose of Elspar and imaging studies
studies. PIs-Drs. Jeanne Larson and Sara Allstadt Frazier, contact
at jlarson8@utk.edu or sarafrazier@utk.edu or 865-974-8387.
8387. Patients need to be newly diagnosed within 7 days of
enrollment and not on other therapy. After the study period ends, they may go on to receive other chemotherapy
treatments.

Tumor type: CANINE
NE MAST CELL TUMOR
TUMOR.
Trial: Use of Kinavet (masitinib) for non
non-resectable canine mast cell tumors.
This is a double-blinded placebo-control
control trial that evaluates Kinavet in dogs with non-resectable
resectable mast cell tumors
(2/3 of the dogs will receive Kinavet, 1/3 –placebo). Dogs cannot be on chemotherapy and should be off steroids for
at least 3 weeks. A screening visit to determine eligibility is required. The trial is fully funded.
funded PI- Dr. Olya
Smrkovski, contact: (865) 974-8387
8387 or email: opuretsk@utk.edu.
CARCINOMA.
Tumor Type: CANINE THYROID CARCI
Trial: Evaluation of a novel hand held device to monitor response of canine thyroid carcinomas to
radiation therapy. The trial period is 3 weeks. This trial includes a financial incentive of $500. PI: Dr. Nathan
Lee, contact at nlee9@utk.edu or 865-755
755-8571.
Tumor type: CANINE TRANSITIONAL CELL CARCINOMA.
Trial: Pilot study, Neurotransmitter levels in blood samples of dogs with and without transitional
cell carcinoma.
Research by Dr. Schuller's lab has shown that high blood levels of cancer stimulating stress neurotransmitters can
stimulate certain cancer types in vitro and in rodent animal models. The current pilot study will explore blood
samples in dogs with transitional cell carcinoma to determine if they have increased stress neurotransmitter levels
and/or decreased GABA levels. Patients must be untreated (N
(NSAIDs
SAIDs are not allowed). Patients can present to UT or
referring practitioners may submit blood for use in this study. A 5ml blood sample is needed for studystudy no cost to
client for participation. (PI- Dr. Hildegard M. Schuller; Co
Co-investigators: Drs. Joe Bartges
rtges and Sara Allstadt Frazier)
COMING SOON: Tumor Type: OSTEOSARCOMA
Trial: Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs with Osteosarcoma.
Several lines of evidence suggest that blockade of the mTOR pathway may be an effective strategy to prevent
metastatic cancer progression. This study seeks to identify an optimal dose of the mTOR inhibitor, rapamycin, to
be advanced to a canine clinical trial that will assess the role of rapamycin as an antimetas
antimetastatic
tatic agent in dogs with
osteosarcoma. An open label, prospective preclinical trial of orally administered rapamycin will be conducted in
dogs with osteosarcoma. This is a fixed schedule, dose escalation study in dogs with measurable tumors. Data from
the initial pilot PK analysis will help determine the doses to be evaluated in the dose escalation study. The primary
objective of this study is to identify a tolerable chronic exposure of oral rapamycin in tumor-bearing
tumor
dogs that is
achievable in human patients
ts and has been demonstrated to inhibit metastatic progression in murine models.
Toxicity will be evaluated via dose escalation and assessment of dose limiting toxicities (DLT) and parallel
assessment of pharmacokinetic exposures. The study is FULLY FUNDED and will provide rapamycin for dogs that
respond for up to 6 months of treatment. (PI
(PI-Dr. Sara Allstadt Frazier, sarafrazier@utk.edu )
COMING SOON: Tumor type: CANINE BLADDER TRANS
TRANSITIONAL
ITIONAL CELL CARCINOMA
CARCINO
Trial: Evaluating a novel optical imaging agent, fluorocoxib A, to detect cyclooxygenase-2
cyclooxygenase (COX-2)
expressing cancers of bladder in dogs. COX-2
2 enzyme is highly present in cancer cells, but not in normal cells
that makes an attractive target for detection of canc
cancer.
er. This study using fluorocoxib A in dogs with naturally
occurring cancers will assist to identify tumors that would benefit from COX
COX-2
2 targeted NSAIDs. In addition, this
study will assist to translate this novel imaging agent into clinical applications ffor
or detection of cancer, as well for
monitoring the early responses to therapy not only in dogs, but also in human patients. This trial includes
financial incentives to the client. Patients may be enrolled undiagnosed and the trial will pay for biopsy for
diagnosis.
iagnosis. Patients must be off NSAIDs for 2 weeks before enrollment or biopsy. Trial period is approximately 24
hours. (PIs- Drs. Maria Cekanova and Joe Bartges; please contact Amanda Callens at (865) 974-8387).
974
Contact information listed is for the conve
convenience of referring veterinarians to contact with any
questions prior to referral. Please don’t share contact information of specialists with clients.
C
are
Please note: For all trials, patients must be examined at UTCVM to determine eligibility. Clients
often responsible for the initial examination fee for the first visit (currently $
$129
9) and any tests
required by that trial to determine eligibility (many trials require some staging tests performed to
determine eligibility but some may cover the cost of some tests).. Each trial has different funding
and an explanation of covered costs and non
non-covered
covered costs will be reviewed with each case.
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